Literature DB >> 33291672

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.

Mara N Zeissig1,2, Andrew C W Zannettino1,2,3,4, Kate Vandyke1,2.   

Abstract

Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral blood MM PCs are associated with rapid disease progression, shorter time to relapse and are a feature of advanced disease. In this review, the current understanding of the process of MM PC dissemination and the extrinsic and intrinsic factors potentially driving it are addressed through analysis of patient-derived MM PCs and MM cell lines as well as mouse models of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups that present with highly disseminated disease, such as t(4;14), t(14;16) and t(14;20), suggest that intrinsic properties of MM PC influence their ability to disseminate. Finally, we discuss the possibility of using therapeutic targeting of tumour dissemination to slow disease progression and prevent overt relapse.

Entities:  

Keywords:  dissemination; metastasis; multiple myeloma

Year:  2020        PMID: 33291672      PMCID: PMC7761917          DOI: 10.3390/cancers12123643

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  140 in total

Review 1.  Plasma-cell homing.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

2.  t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.

Authors:  Gang An; Yan Xu; Lihui Shi; Dehui Zou; Shuhui Deng; Weiwei Sui; Zhenqing Xie; Mu Hao; Hong Chang; Lugui Qiu
Journal:  Leuk Res       Date:  2013-08-05       Impact factor: 3.156

3.  Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Authors:  Luigia Lombardi; Giulia Poretti; Michela Mattioli; Sonia Fabris; Luca Agnelli; Silvio Bicciato; Ivo Kwee; Andrea Rinaldi; Domenica Ronchetti; Donata Verdelli; Giorgio Lambertenghi-Deliliers; Francesco Bertoni; Antonino Neri
Journal:  Genes Chromosomes Cancer       Date:  2007-03       Impact factor: 5.006

4.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Authors:  H Avet-Loiseau; J Y Li; T Facon; C Brigaudeau; N Morineau; F Maloisel; M J Rapp; P Talmant; F Trimoreau; A Jaccard; J L Harousseau; R Bataille
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

5.  A new class of membrane-bound chemokine with a CX3C motif.

Authors:  J F Bazan; K B Bacon; G Hardiman; W Wang; K Soo; D Rossi; D R Greaves; A Zlotnik; T J Schall
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

6.  Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.

Authors:  M Pérez-Andrés; J Almeida; M Martín-Ayuso; M J Moro; G Martín-Nuñez; J Galende; D Borrego; M J Rodríguez; F Ortega; J Hernandez; I Moreno; M Domínguez; G Mateo; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

7.  CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis.

Authors:  Jong-Ho Lee; Ha-Neui Kim; Kyung-Ok Kim; Won Jong Jin; Seungbok Lee; Hong-Hee Kim; Hyunil Ha; Zang Hee Lee
Journal:  Cancer Res       Date:  2012-05-04       Impact factor: 12.701

8.  Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Jihye Park; Robert Redd; Benny Zhitomirsky; Andrew J Dunford; Karma Salem; Yu-Tzu Tai; Shankara Anand; Tarek H Mouhieddine; Selina J Chavda; Cody Boehner; Liudmila Elagina; Carl Jannes Neuse; Justin Cha; Mahshid Rahmat; Amaro Taylor-Weiner; Eliezer Van Allen; Shaji Kumar; Efstathis Kastritis; Ignaty Leshchiner; Elizabeth A Morgan; Jacob Laubach; Tineke Casneuf; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson; Lorenzo Trippa; François Aguet; Chip Stewart; Meletios-Athanasios Dimopoulos; Kwee Yong; P Leif Bergsagel; Salomon Manier; Gad Getz; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 50.717

9.  High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

Authors:  G Bianchi; R A Kyle; D R Larson; T E Witzig; S Kumar; A Dispenzieri; W G Morice; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528

10.  Progression signature underlies clonal evolution and dissemination of multiple myeloma.

Authors:  Yu Jia Shen; Yuji Mishima; Jiantao Shi; Romanos Sklavenitis-Pistofidis; Robert A Redd; Michele Moschetta; Salomon Manier; Aldo M Roccaro; Antonio Sacco; Yu-Tzu Tai; Francois Mercier; Yawara Kawano; Nang Kham Su; Brianna Berrios; John G Doench; David E Root; Franziska Michor; David T Scadden; Irene M Ghobrial
Journal:  Blood       Date:  2021-04-29       Impact factor: 25.476

View more
  4 in total

Review 1.  Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.

Authors:  Annette Gilchrist; Stephanie L Echeverria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-25       Impact factor: 5.555

2.  Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression.

Authors:  Fabrizio Fontana; Martina Anselmi; Patrizia Limonta
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

3.  Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming.

Authors:  Yuanzheng Liang; Haiyan He; Weida Wang; Henan Wang; Shaowen Mo; Ruiying Fu; Xindi Liu; Qiong Song; Zhongjun Xia; Liang Wang
Journal:  Mol Cancer       Date:  2022-09-22       Impact factor: 41.444

4.  CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.

Authors:  Katia Beider; Valeria Voevoda-Dimenshtein; Ali Zoabi; Evgenia Rosenberg; Hila Magen; Olga Ostrovsky; Avichai Shimoni; Lola Weiss; Michal Abraham; Amnon Peled; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2022-10-10       Impact factor: 23.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.